Agenus (AGEN) Operating Income (2010 - 2026)
Agenus (AGEN) posted quarterly Operating Income of $15.1 million for Q1 2026, up 213.09% year-over-year from $4.8 million in Q1 2025, and up 4.56% quarter-over-quarter from $14.4 million in Q4 2025.
Agenus (AGEN) Operating Income (2010 - 2026) Analysis & Trends
Agenus' Operating Income history runs 17 years deep, the most recent figure standing at $15.1 million for Q1 2026.
- In Q1 2026, Operating Income rose 213.09% year-over-year to $15.1 million; the TTM figure through Mar 2026 stood at $8.2 million (up 108.12% YoY), while the FY2025 annual figure was -$20.2 million, up 83.26% from the prior year.
- Operating Income for Q1 2026 stood at $15.1 million, up from $14.4 million in the prior quarter.
- The five-year high for Operating Income was $15.1 million in Q1 2026, with the low at -$57.8 million in Q4 2022.
- The 5-year median for Operating Income is -$31.5 million (2024), against an average of -$27.3 million.
- The sharpest annual moves came in 2024 and 2026: Operating Income sank 516.42% in 2024, then jumped 213.09% in 2026.
- Agenus' Operating Income stood at -$57.8 million in 2022, then jumped by 92.73% to -$4.2 million in 2023, then tumbled by 516.42% to -$25.9 million in 2024, then surged by 155.6% to $14.4 million in 2025, then gained by 4.56% to $15.1 million in 2026.
- Business Quant data shows AGEN's Operating Income at $15.1 million in Q1 2026, $14.4 million in Q4 2025, and -$4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Agenus | 311.95 Mn | 286.43 Mn | 34.52 Mn | 11.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.29 Mn |
| Mar 31, 2026 | 15.05 Mn |
| Dec 31, 2025 | 14.40 Mn |
| Sep 30, 2025 | -4.55 Mn |
| Jun 30, 2025 | -16.71 Mn |
| Mar 31, 2025 | -13.31 Mn |
| Dec 31, 2024 | -25.90 Mn |
| Sep 30, 2024 | -31.50 Mn |
| Jun 30, 2024 | -30.19 Mn |
| Mar 31, 2024 | -32.88 Mn |
| Dec 31, 2023 | -4.20 Mn |
| Sep 30, 2023 | -46.34 Mn |
| Jun 30, 2023 | -54.67 Mn |
| Mar 31, 2023 | -54.34 Mn |
| Dec 31, 2022 | -57.76 Mn |
| Sep 30, 2022 | -41.65 Mn |
| Jun 30, 2022 | -44.57 Mn |
| Mar 31, 2022 | -35.46 Mn |
| Dec 31, 2021 | -54.03 Mn |
| Sep 30, 2021 | 187.54 Mn |